NEW TREATMENTS FOR PATIENTS WITH MENTAL ILLNESS
Associate Professor Bernadette Fitzgibbon
Director of Psychiatry Research
Paratus Clinical, Australia &
Associate Professor,
Australian National University, Canberra, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | November 2025
Associate Professor Bernadette Fitzgibbon is a neuroscientist with several decades of experience in researching, developing, and translating novel therapies for mental health and chronic pain conditions. This includes the application and optimisation of brain stimulation and psychedelic therapies, overseeing large multi-site intervention trials, both within Australia and abroad. Through her work, she has developed meaningful collaborations with consumers, volunteers, policy makers, and services providers, ensuring that the outcomes of her work contribute towards real-world clinical impact.
She is currently the Director of Psychiatry Research at Paratus Clinical, where she leads the delivery of clinical trials in emerging therapies for psychiatry, collaborating with academic institutions, pharmaceutical and biotechnology companies. She is also an Associate Professor at the Australian National University, where she contributes to novel investigator-initiated trials within interventional psychiatry and clinical neuroscience, and a consultant at The Psychedelic Consultancy: a hub to connect and support professionals navigate the legal psychedelic assisted psychotherapy ecosystem in Australia and internationally. Together, she is dedicated to changing the landscape of mental health treatments to improve the outcomes for people living with mental illness.
Source: Supplied
https://orcid.org/0000-0002-5339-5304
-
Stem cells used for age-related macular degeneration
Dr. Jenna Hall is a passionate and accomplished biologist with expertise in induced pluripotent stem cell (iPSC) culture, disease modelling, and high-throughput automated systems. She recently earned her PhD from the University of Melbourne, where her research focused on using iPSC-derived retinal pigment epithelium (RPE) cells to study age-related macular degeneration. Dr Hall’s technical skillset spans manual and automated cell reprogramming and differentiation, quantitative microscopy-based phenotyping, and large scale -omics analysis.
-
Earlier identification and early intervention for children who are deaf or hard of hearing
As Director of NextSense Institute, Professor Leigh is responsible for leading the not-for-profit organisation’s world-class research and education programs and facilities. He has held a variety of positions in the education of children who are deaf or hard of hearing before entering academia. He holds a degree in Special Education from Griffith University, a Master of Science (Speech and Hearing) from Washington University and a PhD in Special Education from Monash University. In 2001, he was made a Fellow of the Australian College of Educators and in 2014, he was invested as an Officer in the Order of Australia (AO) for distinguished services to the deaf and hard of hearing community.
-
Non-invasive tools for CVD screening and monitoring
Dr Hadi Afsharan is a Research Fellow Cardiovascular Science & Diabetes at the Harry Perkins Institute of Medical Research; is a translational research and innovation fellow in medical technologies at The University of Western Australia, holding dual titles as Translational Fellow and Innovation Fellow within UWA’s Medical School and the FHRI (Future Health Research and Innovation) program.
